

Article



Structural Determination of Ruthenium Complexes Containing Bi-Dentate Pyrrole-Ketone Ligands

Ya-Wen Tsai¹, Yun-Fan Chen¹, Yong-Jie Li¹, Kuan-Hung Chen¹, Chia-Her Lin² ^(D) and Jui-Hsien Huang^{1,*}

- ¹ Department of Chemistry, National Changhua University of Education, Changhua 50058, Taiwan; s0225019@gmail.com (Y.-W.T.); evons44@gmail.com (Y.-F.C.); Jack100960503@gmail.com (Y.-J.L.); k19920922@yahoo.com.tw (K.-H.C.)
- ² Department of Chemistry, Chung-Yuan Christian University, Chun-Li 320, Taiwan; chiaher@cycu.edu.tw
- * Correspondence: juihuang@cc.ncue.edu.tw; Tel.: +886-4-7232105 (ext. 3512)

Received: 19 December 2017; Accepted: 12 January 2018; Published: 13 January 2018

Abstract: A series of ruthenium compounds containing a pyrrole-ketone bidentate ligand, 2-(2'-methoxybenzoyl)pyrrole (**1**), have been synthesized and characterized. Reacting **1** with $[(\eta^6 - cymene)RuCl_2]_2$ and RuHCl(CO)(PPh₃)₃ generated Ru(η^6 -cymene)[C₄H₃N-2-(CO-C₆H₄-2-OMe)]Cl (**2**) and {RuCl(CO)(PPh₃)₂[C₄H₃N-2-(COC₆H₄-2-OMe)]} (**3**), respectively, in moderate yields. Successively reacting **2** with sodium cyanate and sodium azide gave {Ru(η^6 -cymene)[C₄H₃N-2-(CO-C₆H₄-2-OMe)]X} (**4**, X=OCN; **5**, X=N₃) with the elimination of sodium chloride. Compounds **2–5** were all characterized by ¹H and ¹³C-NMR spectra and their structures were also determined by X-ray single crystallography.

Keywords: ruthenium; pyrrole-ketone; cymene; ruthenium-hydride

1. Introduction

Ruthenium compounds [1–3] containing varieties of ligands, such as cymene [4,5], phosphine [6] NHC [7], keto-amine [8,9], and Schiff-base [10,11], represent an important chemical series on the field of medicinal chemistry [12–15] and catalytic transfer hydrogenation [16–18] etc. Finely tuned ruthenium complexes can be achieved by changing the coordinating ligands. Therefore, by combining suitable ruthenium complexes with organic ligands and studying their structural geometries may shed some light on the understanding of the functions of these ruthenium complexes.

Among of these ruthenium compounds, $[(\eta^6-cymene)RuCl_2]_2$ [19] and RuHCl(CO)(PPh₃)₃ [20] are two important starting materials for synthesizing corresponding ruthenium compounds due to their versatile applications [21–24]. Pyrrole represents an important heterocyclic compound for forming materials such as hemes and porphyrinc [25,26], ion-receptors [27,28], bio-active products [29–31], and light-harvesting pigments [32], etc. Its related compound, 2-(2'-methoxybenzoyl)pyrrole (1) [33–35], a multi-dentate ligand, was isolated from the mycelia extract [36] and exhibits bio-activity [37,38].


Here we report the synthesis and structural characterization of a series of ruthenium compounds containing the multidentate pyrrole-ketone ligand. The successive reacting of these ruthenium complexes with sodium salts of NaOCN and NaN₃ is also reported. These compounds were structurally determined in order to understand their steric geometries for further applications.

2. Results and Discussion

2.1. Synthesis and Characterization

A series of ruthenium compounds containing 2-(2'-methoxybenzoyl)pyrrole (1) was synthesized and characterized. A reaction scheme of 1 with $[(\eta^6-cymene)RuCl_2]_2$ and $RuHCl(CO)(PPh_3)_3$ is shown

in Scheme 1. Reacting $[(\eta^6\text{-cymene})\text{RuCl}_2]_2$ with two equivalents of 1 in methanol solution at room temperature in the presence of sodium bicarbonate gave a 32.0% yield of $\text{Ru}(\eta^6\text{-cymene})[C_4\text{H}_3\text{N}-2-(\text{CO-C}_6\text{H}_4\text{-2-OMe})]\text{Cl}$ (2). The ¹H-NMR spectrum of 2 showed four doublets in the range of δ 5.62~5.35 representing the arene CH protons of the cymene fragment. Similarly, while reacting 1 with RuHCl(CO)(PPh_3)_3 in toluene under refluxing and work-up, the resulting product {RuCl(CO)(PPh_3)_2 [C_4\text{H}_3\text{N}-2-(\text{COC}_6\text{H}_4\text{-2-OMe})]} (3) was prepared in a 66.9% yield along with the elimination of one equivalent of hydrogen molecules. The ¹H-NMR spectrum of 3 showed the pyrrole CH chemical shifts at δ 5.50, 5.59, and 6.65. Due to the weak hydrogen bonding, the isopropyl fragment showed two doublets in the ¹H-NMR spectrum representing the slow C-C bond rotation of the isopropyl and the cymene phenyl ring. The ¹³C-NMR spectra of 3 showed two chemical shifts at δ 205.6 and 183.4, assigned as the carbon of C=O and C=O, respectively [39,40]. The IR spectrum of $\mathbf{Z} = \mathbf{O}$ [41,42].



Scheme 1. Synthesis of Compounds 2–5.

Successively replacing the chloride anion of **2** with sodium salts of NaX in methanol resulted in new ruthenium compounds { $Ru(\eta^6-cymene)[C_4H_3N-2-(CO-C_6H_4-2-OMe)]X$ } (**4**, X=OCN; **5**, X=N_3). Compounds **4** and **5** were both characterized by ¹H and ¹³C-NMR spectra and showed patterns similar to those of Compound **2**, indicating that the electronic properties around the ruthenium atom was not affected by the coordinated mono-anionic ligands.

2.2. Molecular Geometries of Compounds 2–5

Single-crystals of Compounds 2–5 for X-ray diffraction analysis were obtained from either methanol or THF saturated solution at -20 °C. The summary of the X-ray crystal data and selected bond lengths and angles are shown in Tables 1 and 2, respectively. The molecular geometries of 2–5 are depicted in Figures 1–4. The molecular geometry of 2 could be described as a three-legged piano stool with the nitrogen atom of the pyrrole, the oxygen atom of the carbonyl atoms, and the chloride atom forming the three legs and the cymene ring acting as the stool plane. The bond length of the ruthenium atom to the center of the cymene ring is 1.6598(1) Å, relatively close to the bond lengths of published ruthenium-cymene compounds [41,42]. It is interesting to note that the methine proton (H8) of the cymene ring was close to the oxygen atom (O2) of the methoxy group of ligand 1, with a bond length of 2.511 Å, which is assumed to be a weak hydrogen bonding between the H8 and O2 atoms [43].

	2	3 THF	4	5
formula	C ₂₂ H ₂₄ ClNO ₂ Ru	C ₅₃ H ₄₈ ClNO ₄ P ₂ Ru	C ₂₃ H ₂₄ N ₂ O ₃ Ru	C ₂₂ H ₂₄ N ₄ O ₂ Ru
FW	470.94	961.38	477.51	477.52
T [K]	150(2)	150(2)	150(2)	150(2)
crystal system	Monoclinic	Monoclinic	Monoclinic	Monoclinic
space group	$P2_1/n$	$P2_1/n$	$P2_1/c$	$P2_1/c$
a [Å]	10.4657(4)	10.2279(5)	10.157(5)	17.3849(14)
b [Å]	9.1505(3)	17.5822(9)	15.836(7)	9.2423(7)
<i>c</i> [Å]	21.1478(8)	25.9234(13)	14.019(8)	13.8157(11)
α [°]	90	90	90	90
β [°]	99.097(2)	97.693(3)	105.44(3)	112.379(4)
γ [°]	90	90	90	90
<i>V</i> [Å ³]	1999.78(13)	4619.8(4)	2173.5(19)	2052.7(3)
Z	4	4	4	4
$ ho_{\rm c} [{ m Mg}{ m m}^{-3}]$	1.564	1.382	1.465	1.545
μ [mm ⁻¹]	0.934	0.513	0.748	0.787
F(000)	960	1824	980	976.0
rflns collected	28,629	49,633	26,439	18,124
independent rflns	5176 [R _{int} = 0.0263]	8132 [R _{int} = 0.0979]	5380 [R _{int} = 0.0893]	5243 [R _{int} = 0.0298]
lata/restraints/parameters	5176/0/248	8132/0/560	5380/0/266	5243/0/266
goodness-of-fit on <i>F</i> ²	1.027	0.880	0.968	1.067
$P = \pi P (I > 2\sigma(I))$	$R_1 = 0.0208$	$R_1 = 0.0591$	$R_1 = 0.0568$	$R_1 = 0.0306$
$R_1, wR_2 \ (I > 2\sigma(I))$	$wR_2 = 0.0494$	$wR_2 = 0.1682$	$wR_2 = 0.1449$	$wR_2 = 0.0783$
R_{1} πR_{2} (all data)	$R_1 = 0.0260$	$R_1 = 0.0879$	$R_1 = 0.0890$	$R_1 = 0.0356$
R_1 , wR_2 (all data)	$wR_2 = 0.0520$	$wR_2 = 0.1925$	$wR_2 = 0.1724$	$wR_2 = 0.0810$
argest diff. peak, hole $[eÅ^{-3}]$	0.406 and −0.367	0.811 and -0.925	1.071 and -2.014	0.870 and -0.699

 Table 1. The summary of X-ray crystal data for Compounds 2–5.

		2	
Ru(1)-Cl(1)	2.4092(5)	Ru(1)-N(1)	2.060(1)
Ru(1)-O(1)	2.103(1)	Ru(1)-Cymene	1.6598(1)
O(1)-C(15)	1.273(2)	N(1)-Ru(1)-O(1)	77.09(5)
Cl(1)-Ru(1)-N(1)	85.41(4)	Cl(1)-Ru(1)-O(1)	85.53(3)
		3	
Ru(1)-C(50)	1.845(7)	Ru(1)-N(1)	2.038(5)
Ru(1)-O(1)	2.139(4)	Ru(1)-P(1)	2.4058(15)
O(1)-C(15)	1.273(2)	Ru(1)-P(2)	2.3908(15)
Ru(1)-Cymene	1.6598(1)	Ru(1)-Cl(1)	2.4185(15)
O(1)-C(41)	1.280(7)	C(50)-O(4)	1.128(8)
C(50)-Ru(1)-O(1)	172.9(2)	P(2)-Ru(1)-P(1)	177.38(5)
N(1)-Ru(1)-Cl(1)	166.70(14)	N(1)-Ru(1)-O(1)	78.32(16)
		4	
Ru(1)-N(1)	2.070(5)	Ru(1)-N(2)	2.057(3)
Ru(1)-O(2)	2.124(3)	Ru(1)-Cymene	1.6674(7)
O(2)-C(5)	1.278(5)	N(1)-C(23)	1.155(6)
O(1)-C(23)	1.218(6)	Ru(1)-N(1)-C(23)	156.9(4)
N(1)-Ru(1)-N(2)	84.53(16)	N(2)-Ru(1)-O(2)	77.03(13)
N(1)-Ru(1)-O(2)	83.61(16)	N(1)-C(23)-O(1)	176.3(6)
		5	
Ru(1)-N(1)	2.109(2)	Ru(1)-N(2)	2.0640(19)
Ru(1)-O(1)	2.1114(15)	Ru(1)-Cymene	1.6610(2)
O(1)-C(15)	1.276(3)	N(1)-N(2)	1.204(3)
N(2)-N(3)	1.157(3)	N(4)-Ru(1)-O(1)	77.08(7)
N(1)-Ru(1)-N(4)	86.02(8)	N(1)-Ru(1)-O(1)	86.62(7)
Ru(1)-N(1)-N(2)	120.43(17)	N(1)-N(2)-N(3)	176.7(3)

Table 2. Selected bond lengths (Å) and angles (°) for Compounds 2–5.




Figure 1. The molecular geometry of Compound **2**. The thermal ellipsoids were drawn at 50% probability and all the hydrogen atoms except the methine proton on the cymene ring were omitted for clarity. The H8-O2 hydrogen bonding is shown.




Figure 2. The molecular geometry of Compound **3**. The thermal ellipsoids were drawn at 50% probability and all the hydrogen atoms were omitted for clarity.




Figure 3. The molecular geometry of Compound **4**. The thermal ellipsoids were drawn at 50% probability and all the hydrogen atoms were omitted for clarity.




Figure 4. The molecular geometry of Compound 5. The thermal ellipsoids were drawn at 50% probability and all the hydrogen atoms except the methine proton on the cymene ring were omitted for clarity. The H8-O2 hydrogen bonding is shown.

The molecular geometry of **3** is shown in Figure 2 and the THF molecule was omitted for clarity. It can be described as a distorted octahedral with three axes of Cl(1)-Ru(1)-N(1), O(1)-Ru(1)-C(50), and P(1)-Ru(1)-P(2) with angles of 166.70(14)°, 172.9(2)°, and 177.38 (5)°, respectively. The ligand **1** binds to the ruthenium atom in an acute chelating angle of N(1)-Ru(1)-O(1) at 78.32(16)°. The bond lengths of Ru(1)-C(50) and C(50)-O(4) are 1.845(7) Å and 1.128(8) Å, respectively, indicating a slight back bonding of the ruthenium atom to the carbonyl and the longer C \equiv O bond. The results are in agreement with reported trans-RuCl(CO)(PPh₃)₂(bidentate) structures [44–48].

The molecular geometry of 4 can also be described as a three-legged piano stool geometry, as shown in Figure 3. The bond length from the ruthenium atom to the center of the cymene ring is at ca. 1.667 Å. The ambi-dentate NCO ligand was bound to the ruthenium atom at the N-end. Similar ruthenium cymene-NCO structures have been reported in the literature [49,50]. The bond lengths of ruthenium to the cyanate-N atom as well as N=C and C=O are all consistent with the results in the literature.

The pale orange crystals of **5** were obtained from a saturated methanol solution at -20 °C. The molecular structure of **5** is shown in Figure 4 and its geometry is similar to that of **2**. It can also be described as a three-legged piano stool geometry with the azide and pyrrolyl nitrogen atoms and carboxyl oxygen atom taking the three leg positions and the cymene acting as the planar surface. The bond length of O(2)-H(8) was ca. 2.868 Å, indicating a very weak or no hydrogen bonding effect. Ru(cymene)azido compounds have been reported in the literature [51–54]. For **5**, the bond lengths of Ru(1)-N(1), N(1)-N(2), and N(2)-N(3) were 2.109(2) Å, 1.204(3) Å, and 1.157(3) Å, respectively and these data are consistent that reported in the literature.

3. Experimental Section

3.1. General Consideration

All reactions were performed under a nitrogen atmosphere using standard Schlenk techniques or in a glove box. Toluene was dried by refluxing over sodium benzophenone ketyl. CH_2Cl_2 was dried over P_2O_5 . All solvents were distilled and stored in solvent reservoirs that contained 4-Å molecular sieves and were purged with nitrogen. The ¹H and ¹³C-NMR spectra were recorded using a Bruker Avance 300 spectrometer and the chemical shifts were recorded in ppm relative to the residual protons of CDCl₃ (δ = 7.24, 77.0 ppm). Elemental analyses were performed using a Heraeus CHN-OS Rapid Elemental Analyzer at the Instrument Center of the NCHU. Ligands [33–35] **1** and [Ru(η^6 -p-cymene)Cl₂]₂ were prepared using a modified procedure [19].

3.1.1. Synthesis of the Ligand $[C_4H_3NH-2-(CO-C_6H_4-2-OMe)]$ (1)

A Schlenk flask charged with pyrrole (0.38 g, 5.7 mmol) and 15 mL of toluene was added to equimolar MeMgBr (3.0 M, 1.9 mL) at 0 °C. The resulting solution was then refluxing for 30 min under nitrogen. The color changed from bright yellow back to orange. Methoxybenzoyl chloride (0.97 g, 5.7 mmol) was then added to the resulting solution at room temperature and the solution color changed back to yellow again. Ammonium chloride water solution was added to the solution after 30 min and the combing solution was extracted with diethyl ether (10 mL × 3). The extraction was dried over MgSO₄ and volatiles were removed to give ligand 1 in a 63.0% yield (0.727 g). ¹H-NMR (CDCl₃): 3.80 (s, 3H, OMe), 6.24 (m, 1H, pyr CH), 6.62 (m, 1H, pyr CH), 6.99 (m, 2H, phenyl CH), 7.10 (m, 1H, pyr CH), 7.42 (m, 2H, phenyl CH), 10.12 (s, 1H, pyr NH).

3.1.2. Synthesis of Compound { $Ru(\eta^6$ -cymene)[C₄H₃N-2-(CO-C₆H₄-2-OMe)]Cl} (2)

A methanol solution (10 mL) of **1** (0.20 g, 0.99 mmol) and $[Ru(\eta^6-p-cymene)Cl_2]_2$ (0.304 g, 0.50 mmol) in a 50 mL of flask was stirred for 1 h at room temperature. Sodium bicarbonate then was added into the solution and stirred for 3 h. The volatiles were removed under vacuum and the solid was extracted with methylene chloride and then solvent was removed again to give crude product of **2**. The product was recrystallized from a methanol solution to generate 0.149 g of red brown crystals in a 32.0% yield. ¹H-NMR (CDCl₃): 1.21 (d, 3H, CHMe₂), 1.23 (d, 3H, CHMe₂), 2.30 (s, 3H, Me), 2.81 (sept, $J_{HH} = 7.2$ Hz, 1H, CHMe₂), 3.77 (s, 3H, OMe), 5.35 (d, $J_{HH} = 6.0$ Hz, 1H, cymene CH), 5.40 (d, $J_{HH} = 6.0$ Hz, 1H, cymene CH), 5.55 (d, $J_{HH} = 5.7$ Hz, 1H, cymene CH), 5.62 (d, $J_{HH} = 5.7$ Hz, 1H, cymene CH), 6.37 (m, 1H, pyr CH), 6.79 (m, 1H, pyr CH), 7.36 (m, 5H, phenyl C₆H₄ + pyr CH). ¹³C-NMR (CDCl₃): 18.9 (cymene CH), 81.8 (cymene CH), 82.0 (cymene CH), 83.5 (cymene CH), 98.4 (cymene C_{ipso}), 100.5 (cymene C_{ipso}), 111.8 (pyr CH), 116.1 (pyr CH), 120.4 (phenyl CH), 123.4 (phenyl CH), 125.5 (pyr C_{ipso}), 131.4 (phenyl CH), 132.1 (phenyl CH), 141.8 (phenyl C_{ipso}), 143.1 (pyr CH), 157.7 (phenyl C_{ipso}), 186.7 (C=O). Anal. Calcd for C₂₂H₂₄ClNO₂Ru: C, 56.11; H, 5.14; N, 2.97. Found: C, 56.08; H, 5.15; N, 3.36.

3.1.3. Synthesis of Compound $\{RuCl(CO)(PPh_3)_2[C_4H_3N-2-(COC_6H_4-2-OMe)]\}$ (3)

A toluene solution (10 mL) of **1** (0.08 g, 0.40 mmol) and RuHCl(CO)(PPh₃)₃ (0.378 g, 0.40 mmol) in a 50 mL of flask was refluxed for 24 h under nitrogen. The volatiles were removed under vacuum and residue was washed with heptane to remove excess of PPh₃. The resulting solid was recrystallized from a saturated THF solution at -20 °C to give 0.24 g of yellow crystals in a 66.9% yield. ¹H-NMR (CDCl₃): 3.31 (s, 3H, OMe), 5.50 (t, 1H, pyr CH), 5.59 (m, 1H, pyr CH), 6.20 (m, 1H, phenyl CH), 6.40 (m, 1H, phenyl CH), 6.65 (m, 2H, pyr + phenyl CH), 7.30 (m, 31H, PPh₃ CH+ phenyl CH). ¹³C-NMR (CDCl₃): 55.0 (OMe), 110.3, 117.3, 119.7, 123.0, 125.4, 126.6, 127.8, 127.9, 128.0, 128.3, 128.6, 128.7, 129.2, 129.5, 130.5, 130.9, 131.0, 131.2, 131.5, 132.2, 134.5, 134.6, 134.7, 141.3, 142.6, 156.3, 183.4 (C=O), 205.6 (C=O). Anal. Calcd for C₄₉H₄₀NO₃P₂ClRu: C, 66.13; H, 4.53; N, 1.57. Found: C, 66.01; H, 4.86; N, 1.53.

3.1.4. Synthesis of Compound { $Ru(\eta^6$ -cymene)[C₄H₃N-2-(CO-C₆H₄-2-OMe)](OCN)} (4)

A 25 mL Schlenk flask charged with **2** (0.117 g, 0.25 mmol), excess sodium cyanate and methanol (10 mL) was stirred at room temperature for overnight. Methanol was removed under vacuum and residue was extracted with methylene chloride (10 mL \times 3). The methylene chloride was removed and residue was recrystallized from a methanol solution at -20 °C to yield 0.045 g of orange crystals of **4** (38.1% yield). ¹H-NMR (CDCl₃): 1.20 (d, 3H, CHM*e*₂), 1.22 (d, 3H, CHM*e*₂), 2.25 (s, 3H, *Me*), 2.74 (sept,

 $J_{\text{HH}} = 6.9 \text{ Hz},1\text{H}, \text{CHMe}_2$), 3.77 (s, 3H, OMe), 5.32 (d, 2H, $J_{\text{HH}} = 6.3 \text{ Hz}$, cymene CH), 5.57 (d, $J_{\text{HH}} = 5.4 \text{ Hz}$, 1H, cymene CH), 5.62 (d, $J_{\text{HH}} = 5.4 \text{ Hz}$, 1H, cymene CH), 6.37 (m, 1H, pyr CH), 6.78 (m, 1H, pyr CH), 7.38 (m, 4H, phenyl C₆H₄ CH), 7.62 (t, 1H, pyr CH). Anal. Calcd for C₂₃H₂₄N₂O₃Ru: C, 57.70; H, 5.06; N, 5.86. Found: C, 57.70; H, 5.18; N, 6.04.

3.1.5. Synthesis of Compound $\{Ru(\eta^6-cymene)[C_4H_3N-2-(CO-C_6H_4-2-OMe)](N_3)\}$ (5)

A 25 mL Schlenk flask charged with **2** (0.047 g, 0.10 mmol), excess sodium azide, and methanol (10 mL) was stirred at room temperature for overnight. Methanol was removed under vacuum and residue was extracted with methylene chloride (10 mL × 3). The methylene chloride was removed and residue was recrystallized from a methanol solution at -20° C to yield 0.026 g of orange crystals of **5** (53.8% yield). ¹H-NMR (CDCl₃): 1.23 (d, 3H, CH*Me*₂), 1.25 (d, 3H, CH*Me*₂), 2.27 (s, 3H, *Me*), 2.78 (sept, *J*_{HH} = 6.9 Hz,1H, CHMe₂), 3.80 (s, 3H, OM*e*), 5.32 (m, 2H, cymene CH), 5.53 (d, *J*_{HH} = 6.0 Hz, 1H, cymene CH), 5.62 (d, *J*_{HH} = 6.0 Hz, 1H, cymene CH), 6.43 (t, 1H, pyr CH), 6.82 (m, 1H, pyr CH), 7.38 (m, 5H, phenyl C₆H₄ + pyr CH). ¹³C-NMR (CDCl₃): 18.4 (cymene *Me*), 22.5 (cymene CH*Me*₂), 22.8 (cymene CH*Me*₂), 31.2 (cymene CHMe₂), 55.9 (OM*e*), 78.9 (cymene CH), 81.7 (cymene CH), 82.4 (cymene CH), 84.2 (cymene CH), 98.7 (arene C), 100.5 (*C*_{*ipso*}), 111.7 (pyr CH), 116.2 (pyr CH), 120.5 (phenyl CH), 123.7 (phenyl CH), 125.2 (*C*_{*ipso*}), 131.6 (phenyl CH), 132.1 (phenyl CH), 142.1 (*C*_{*ipso*}), 143.2 (pyr CH), 157.7 (*C*_{*ipso*}), 187.2 (C=O). Anal. Calcd for C₂₂H₂₄N₄O₂Ru: C, 55.34; H, 5.07; N, 11.73. Found: C, 55.32; H, 5.09; N, 11.75.

3.2. X-ray Crystallography

Suitable crystals of Compounds 2–5 were attached to a fine glass fiber and mounted in goniostat for data collection. Data collections were performed at 150 K under liquid nitrogen vapor for all compounds. Data were collected on a Bruker SMART CCD diffractometer with graphite monochromated Mo-K α radiation. No significant crystal decay was found. Data were corrected for absorption empirically by means of ψ scans. All non-hydrogen atoms were refined with anisotropic displacement parameters. For all the structures, the hydrogen atom positions were calculated and they were constrained to idealized geometries and treated as rigid where the H atom displacement parameter was calculated from the equivalent isotropic displacement parameter of the bound atom. An absorption correction was performed with the program SADABS [55] and the structures of both complexes were determined by direct methods procedures in SHELXS [56] and refined by full-matrix least-squares methods, on F^2 's, in SHELXL [57]. All the relevant crystallographic data and structure refinement parameters are summarized in Table 1.

4. Conclusions

We have successfully employed a bidentate pyrrole-ketone ligand with ruthenium compounds to form a series of Compounds **2–5** and their structures were determined by X-ray single crystallography. A preliminary test of hydrogen transfer reactions of acetophenone and isopropyl alcohol using these ruthenium compounds showed low conversion. We are currently using Compounds **2–5** to investigate the catalytic activities of hydrogen transfer reactions toward varieties of ketones and alcohols and the hydroaminations of inter- and intra-molecular alkenes and alkynes.

Supplementary Materials: Tables for crystal data including H-bonding. Crystallographic data for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publications nos. CCDC-1567212-5 (Compounds 2–5). Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk or www:http://www.ccdc.cam.ac.uk).

Acknowledgments: The authors express their appreciation to the Ministry of Science and Technology, Taiwan for financial support (MOST 105-2113-M-018-005). We also thank the National Center for High-performance Computing for supporting the chemistry database searching.

Author Contributions: YWT, synthesizing and characterizing compounds; YFC, YJL, KHC, CHL, performed the crystal structures data collection and solving the structures; JHH designed the research and wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Dragutan, I.; Dragutan, V.; Demonceau, A. Editorial of special issue ruthenium complex: The expanding chemistry of the ruthenium complexes. *Molecules* **2015**, *20*, 17244–17274. [CrossRef] [PubMed]
- 2. Storr, T. Ligand Design in Medicinal Inorganic Chemistry; John Wiley & Sons, Ltd.: Chichester, UK, 2014.
- 3. Holder, A.A.; Lilge, L.; Browne, W.R.; Lawrence, M.A.W.; Bullock, J.L., Jr. (Eds.) *Ruthenium Complexes: Photochemical and Biomedical Applications*; Wiley-VCH: Weinheim, Germany, 2016.
- Weiss, A.; Berndsen, R.H.; Dubois, M.; Muller, C.; Schibli, R.; Griffioen, A.W.; Dyson, P.J.; Nowak-Sliwinska, P. In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(n⁶-*p*-cymene)Cl₂(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas. *Chem. Sci.* 2014, *5*, 4742–4748. [CrossRef]
- Clavel, C.M.; Păunescu, E.; Nowak-Sliwinska, P.; Griffioen, A.W.; Scopelliti, R.; Dyson, P.J. Discovery of a highly tumor-selective rrganometallic ruthenium(II)-arene complex. *J. Med. Chem.* 2014, *57*, 3546–3558. [CrossRef] [PubMed]
- Sáez, R.; Lorenzo, J.; Prieto, M.J.; Font-Bardia, M.; Calvet, T.; Omeñaca, N.; Vilaseca, M.; Moreno, V. Influence of PPh₃ moiety in the anticancer activity of new organometallic ruthenium complexes. *J. Inorg. Biochem.* 2014, 136, 1–12. [CrossRef] [PubMed]
- Kilpin, K.J.; Crot, S.; Riedel, T.; Kitchen, J.A.; Dyson, P.J. Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: A preliminary investigation into the biological activity of 'click' carbene complexes. *Dalton Trans.* 2014, 43, 1443–1448. [CrossRef] [PubMed]
- 8. Pettinari, R.; Pettinari, C.; Marchetti, F.; Clavel, C.M.; Scopelliti, R.; Dyson, P.J. Cytotoxicity of ruthenium–arene complexes containing β-ketoamine ligands. *Organometallics* **2013**, *32*, 309–316. [CrossRef]
- Pettinari, R.; Marchetti, F.; Pettinari, C.; Petrini, A.; Scopelliti, R.; Clavel, C.M.; Dyson, P.J. Synthesis, structure, and antiproliferative activity of ruthenium(II) arene complexes with *N*,*O*-chelating pyrazolone-based β-ketoamine ligands. *Inorg. Chem.* 2014, *53*, 13105–13111. [CrossRef] [PubMed]
- 10. Garza-Ortiz, A.; Maheswari, P.U.; Siegler, M.; Spek, A.I.; Reedijk, J. A new family of Ru(II) complexes with a tridentate pyridine Schiff-base ligand and bidentate co-ligands: Synthesis, characterization, structure and in vitro cytotoxicity studies. *New J. Chem.* **2013**, *37*, 3450–3460. [CrossRef]
- 11. Chow, M.J.; Licona, C.; Wong, D.Y.Q.; Pastorin, G.; Gaiddon, C.; Ang, W.H. Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly. *J. Med. Chem.* **2014**, *57*, 6043–6059. [CrossRef] [PubMed]
- 12. Allardyce, C.S.; Dyson, P.J. Ruthenium in medicine: Current clinical uses and future prospects. *Platinum Metal. Rev.* **2001**, 45, 62–69.
- Zeng, L.; Gupta, P.; Chen, Y.; Wang, E.; Ji, L.; Chao, H.; Chen, Z.-S. The development of anticancer ruthenium(II) complexes: From single molecule compounds to nanomaterials. *Chem. Soc. Rev.* 2017, 46, 5771–5804. [CrossRef] [PubMed]
- 14. Ronconi, L.; Sadler, P.J. Using coordination chemistry to design new medicines. *Coord. Chem. Rev.* 2007, 251, 1633–1648. [CrossRef]
- 15. Dougan, S.J.; Sadler, P.J. The Design of Organometallic Ruthenium Arene Anticancer Agents. *Chimia* 2007, *61*, 704–715. [CrossRef]
- Sheeba, M.M.; Tamizh, M.M.; Farrugia, L.J.; Endo, A.; Karvembu, R. Chiral (η⁶-*p*-Cymene)ruthenium(II) complexes containing monodentate acylthiourea ligands for efficient asymmetric transfer hydrogenation of ketones. *Organometallics* 2014, *33*, 540–550. [CrossRef]
- 17. Guo, R.; Lough, A.J.; Morris, R.H.; Song, D. Asymmetric hydrogenation of ketones catalyzed by ruthenium hydride complexes of a beta-aminophosphine ligand derived from norephedrine. *Organometallics* **2004**, *23*, 5524–5529. [CrossRef]
- 18. Kalutharage, N.; Yi, C.S. Scope and mechanistic analysis for chemoselective hydrogenolysis of carbonyl compounds catalyzed by a cationic ruthenium hydride complex with a tunable phenol ligand. *J. Am. Chem. Soc.* **2015**, *137*, 11105–11114. [CrossRef] [PubMed]

- 19. Benneth, M.A.; Smith, A.K. Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride. *J. Chem. Soc. Dalton Trans.* **1974**, 233–241. [CrossRef]
- 20. Chatt, J.; Leigh, G.J.; Mingos, D.M.P.; Paske, R.J. Complexes of osmium, ruthenium, rhenium, and iridium halides with some tertiary monophosphines and monoarsines. *J. Chem. Soc. A* **1968**, 2636–2641. [CrossRef]
- Allardyce, C.S.; Dyson, P.J.; Ellis, D.J.; Heath, S.L. [Ru(n⁶-*p*-cymene)Cl₂(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane): A water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. *Chem. Commun* 2001, 1396–1397. [CrossRef]
- 22. Adeniyi, A.A.; Ajibade, P.A. Development of ruthenium-based complexes as anticancer agents: Toward a rational design of alternative receptor targets. *Rev. Inorg. Chem.* **2016**, *36*, 53–75. [CrossRef]
- 23. Clarke, M.J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev. 2003, 236, 209–233. [CrossRef]
- 24. Dyson, P.J. Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development. *Chimia* **2007**, *61*, 698–703. [CrossRef]
- 25. Cox, M.; Lehninger, A.L.; Nelson, D.R. Principles of Biochemistry; Worth Publishers: New York, NY, USA, 2000.
- 26. Shimizu, S. Recent advances in subporphyrins and triphyrin analogues: Contracted porphyrins comprising three pyrrole rings. *Chem. Rev.* **2017**, *117*, 2730–2784. [CrossRef] [PubMed]
- 27. Kim, S.K.; Gross, D.E.; Cho, D.-G.; Lynch, V.M.; Sessler, J.L. *N*-Tosylpyrrolidine calix[4]pyrrole: Synthesis and ion binding studies. *J. Org. Chem.* 2011, *76*, 1005–1012. [CrossRef] [PubMed]
- Maeda, H.; Bando, Y. Recent progress in research on anion-responsive pyrrole-based π-conjugated acyclic molecules. *Chem. Commun.* 2013, 49, 4100–4113. [CrossRef] [PubMed]
- 29. Khajuria, R.; Dham, S.; Kapoor, K.K. Active methylenes in the synthesis of a pyrrole motif: An imperative structural unit of pharmaceuticals, natural products and optoelectronic materials. *RSC Adv.* **2016**, *6*, 37039–37066. [CrossRef]
- 30. Bhardwaj, V.; Gumber, D.; Abbot, V.; Dhiman, S.; Sharma, P. Pyrrole: A resourceful small molecule in key medicinal hetero-aromatics. *RSC Adv.* **2015**, *5*, 15233–15266. [CrossRef]
- 31. Al-Mourabit, A.; Zancanella, M.A.; Tilvi, S.; Romo, D. Biosynthesis, asymmetric synthesis, and pharmacology, including cellular targets, of the pyrrole-2-aminoimidazole marine alkaloids. *Nat. Prod. Rep.* **2011**, *28*, 1229–1260. [CrossRef] [PubMed]
- 32. Trimm, H.H.; Hunter, W., Jr. *Dyes and Drugs-New Uses and Implications*; Apple Academic Press: Toronto, ON, Canada, 2011.
- Kanakis, A.A.; Sarli, V. Total synthesis of (±)-marinopyrrole A via copper-mediated *N*-arylation. *Org. Lett.* 2010, 12, 4872–4875. [CrossRef] [PubMed]
- 34. Hughes, C.C.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Structures, reactivities, and antibiotic properties of the marinopyrroles A–F. *J. Org. Chem.* **2010**, *75*, 3240–3250. [CrossRef] [PubMed]
- 35. Petruso, S.; Bonanno, S.; Caronna, S.; Ciofalo, M.; Maggio, B.; Schillaci, D. Oxidative halogenation of substituted pyrroles with Cu(II). Part IV. Bromination of 2-(2'-hydroxybenzoyl)pyrrole. A new synthesis of bioactive analogs of monodeoxypyoluteorin. *J. Heterocycl. Chem.* **1994**, *31*, 941. [CrossRef]
- Ghigo, G.; Ciofalo, M.; Gagliardi, L.; La Manna, G.; Cramer, C. The electronic spectra of 2-(2'-hydroxybenzoyl) pyrrole and 2-(2'-methoxybenzoyl)pyrrole: A theoretical study. *J. Phys. Org. Chem.* 2005, *18*, 1099–1106. [CrossRef]
- 37. Wang, H.-G.; Amin, S. Mcl-1 Modulating Compositions. Patent WO2013/112878 A1, 1 August 2013.
- Trisuwan, K.; Rukachaisirikul, V.; Sukpondma, Y.; Phongpaichit, S.; Preedanon, S.; Sakayaroj, J. Furo[3,2-*h*]isochroman, furo[3,2-*h*]-isoquinoline, isochroman, phenol, pyranone, and pyrone derivatives from the sea fan-derived fungus Penicillium sp. PSU-F40. *Tetrahedron* 2010, *66*, 4484–4489. [CrossRef]
- Chen, T.; Li, H.; Qu, S.; Zheng, B.; He, L.; Lai, Z.; Wang, Z.-X.; Huang, K.-W. Hydrogenation of esters catalyzed by ruthenium PN3-pincer complexes containing an aminophosphine arm. *Organometallics* 2014, 33, 4152–4155. [CrossRef]
- 40. Anaby, A.; Butschke, B.; Ben-David, Y.; Shimon, L.J.W.; Leitus, G.; Feller, M.; Milstein, D. B–H bond cleavage via metal–ligand cooperation by dearomatized ruthenium pincer complexes. *Organometallics* **2014**, *33*, 3716–3726. [CrossRef]
- 41. Raja, M.U.; Gowri, N.; Ramesh, R. Synthesis, crystal structure and catalytic activity of ruthenium(II) carbonyl complexes containing ONO and ONS donor ligands. *Polyhedron* **2010**, *29*, 1175–1181. [CrossRef]
- 42. Gusev, D.G.; Dolgushin, F.M.; Antipin, M.Y. Hydride, borohydride, and dinitrogen pincer complexes of ruthenium. *Organometallics* **2000**, *19*, 3429–3434. [CrossRef]

- 43. Veljković, D.Z.; Janjića, G.V.; Zarić, S.D. Are C–H···O interactions linear? The case of aromatic CH donors. *CrystEngComm* **2011**, *13*, 5005–5010. [CrossRef]
- 44. Manikandan, T.S.; Saranya, S.; Ramesh, R. Synthesis and catalytic evaluation of ruthenium(II) benzhydrazone complex in transfer hydrogenation of ketones. *Tetrahedron Lett.* **2016**, *57*, 3764–3769. [CrossRef]
- 45. McGuiggan, M.F.; Pignolet, L.H. Synthesis and X-ray structural characterization of an ortho-metalated ruthenium complex of acetophenone. *Inorg. Chem.* **1982**, *21*, 2523–2526. [CrossRef]
- 46. Flower, K.R.; Garrould, M.W.; Leal, L.G.; Mangold, C.; O'Malley, P.J.; Pritchard, R.G. The synthesis, reactivity and modelling studies of [RuCl(CO)(η²-*C*,*O*-C₆H₄-2-CHO)(PPh₃)₂]: Crystal and molecular structures of [RuCl(CO)(η²-*C*,*O*-C₆H₄-2-CHO)(PPh₃)₂]:3.5CHCl₃ and [Ru(NC^tBu)(CO)(η²-*C*,*O*-C₆H₄-2-CHO)(PPh₃)₂][BF₄]·2CHCl₃. J. Organomet. Chem. **2008**, 693, 408–416. [CrossRef]
- 47. Flower, K.R.; Leal, L.G.; Pritchard, R.G. Definitive proof of a Ru-Cl···ClCHCl interaction in the solid state: Crystal and molecular structure of [RuCl(CO)(η²-C,N-C₆H₄CH=NC₆H₄-4-Me)(PPh₃)₂]·CHCl₃. *Inorg. Chem. Commun.* 2004, 7, 729–730. [CrossRef]
- 48. Shivakumar, M.; Pramanik, K.; Ghosh, P.; Chakravorty, A. Isolation and structure of the first azo anion radical complexes of ruthenium. *Inorg. Chem.* **1998**, *37*, 5968–5969. [CrossRef] [PubMed]
- 49. Cadierno, V.; Diez, J.; Garcia-Garrido, S.E.; Garcia-Granda, S.; Gimeno, J. Ruthenium(II) and ruthenium(IV) complexes containing hemilabile heterodifunctional iminophosphorane-phosphine ligands Ph₂PCH₂P(=NR)Ph₂. *J. Chem. Soc. Dalton Trans.* **2002**, 1465–1472. [CrossRef]
- 50. Cadierno, V.; Crochet, P.; Diez, J.; Garcia-Alvarez, J.; Garcia-Garrido, S.E.; Gimeno, J.; Garcia-Granda, S.; Rodriguez, M.A. Ruthenium(II) and ruthenium(IV) complexes containing κ¹-P-, κ²-P,O-, and κ³-P,N,O-iminophosphorane-phosphine ligands Ph₂PCH₂P{=NP(=O)(OR)₂}Ph₂ (R = Et, Ph): synthesis, reactivity, theoretical studies, and catalytic activity in transfer hydrogenation of cyclohexanone. *Inorg. Chem.* **2003**, *42*, 3293–3307. [PubMed]
- 51. Singh, T.; Kishan, R.; Nethaji, M.; Thirupathi, N. Synthesis, reactivity Studies, structural aspects, and solution behavior of half sandwich ruthenium(II) *N*,*N*',*N*''-triarylguanidinate complexes. *Inorg. Chem.* **2012**, *51*, 157–169. [CrossRef] [PubMed]
- Nongbri, S.L.; Das, B.; Rao, K.M. Arene ruthenium β-diketonato triazolato derivatives: Synthesis and spectral studies (β-diketones: 1-phenyl-3-methyl-4-benzoyl pyrazol-5-one, acetylacetone derivatives). *J. Organomet. Chem.* 2009, 694, 3881–3891. [CrossRef]
- Yadav, M.; Singh, A.K.; Maiti, B.; Pandey, D.S. Heteroleptic arene ruthenium complexes based on meso-substituted dipyrrins: Synthesis, structure, reactivity, and electrochemical studies. *Inorg. Chem.* 2009, 48, 7593–7603. [CrossRef] [PubMed]
- 54. Singh, K.S.; Kreisel, K.A.; Yap, G.P.A.; Kollipara, M.R. Synthesis of arene ruthenium triazolato complexes by cycloaddition of the corresponding arene ruthenium azido complexes with activated alkynes or with fumaronitrile. *J. Organomet. Chem.* **2006**, *691*, 3509–3518. [CrossRef]
- 55. Sheldirck, G.M. Area-Detector Absorption Correction (SADABS); Bruker AXS Inc.: Madison, WI, USA, 2004.
- 56. Sheldrick, G.M. SHELX97-Programs for Crystal Structure Analysis: Structure Determination (SHELXS); University of Göttingen: Göttingen, Germany, 1997.
- 57. Sheldrick, G.M. SHELX97-Programs for Crystal Structure Analysis: Refinement (SHELXL); University of Göttingen: Göttingen, Germany, 1997.

Sample Availability: Samples of the Compounds 2–5 are available from the authors.



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).